{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:01:49Z","timestamp":1793674909197,"version":"4.5.1"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Myasthenia gravis (MG) is characterized by muscle weakness and fatigue caused by the presence of autoantibodies against the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK). Activated T, B and plasma cells, as well as cytokines, play important roles in the production of pathogenic autoantibodies and the induction of inflammation at the neuromuscular junction in MG. Many studies have focused on the role of cytokines and lymphocytes in anti-AChR antibody-positive MG. Chronic inflammation mediated by T helper type 17 (Th17) cells, the promotion of autoantibody production from B cells and plasma cells by follicular Th (Tfh) cells and the activation of the immune response by dysfunction of regulatory T (Treg) cells may contribute to the exacerbation of the MG pathogenesis. In fact, an increased number of Th17 cells and Tfh cells and dysfunction of Treg cells have been reported in patients with anti-AChR antibody-positive MG; moreover, the number of these cells was correlated with clinical parameters in patients with MG. Regarding cytokines, interleukin (IL)-17; a Th17-related cytokine, IL-21 (a Tfh-related cytokine), the B-cell-activating factor (BAFF; a B cell-related cytokine) and a proliferation-inducing ligand (APRIL; a B cell-related cytokine) have been reported to be up-regulated and associated with clinical parameters of MG. This review focuses on the current understanding of the involvement of cytokines and lymphocytes in the immunological pathogenesis of MG, which may lead to the development of novel therapies for this disease in the near future.<\/jats:p>","DOI":"10.1111\/cei.13546","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:41:31Z","timestamp":1605256891000},"page":"366-374","source":"Crossref","is-referenced-by-count":156,"title":["Roles of cytokines and T cells in the pathogenesis of myasthenia gravis"],"prefix":"10.1093","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"A","family":"Uzawa","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4574","authenticated-orcid":false,"given":"S","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Neurology, International University of Health and Welfare, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nagane","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Utsugisawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"2021121023213419900_cei13546-bib-0001","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"2021121023213419900_cei13546-bib-0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2021121023213419900_cei13546-bib-0003","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"2021121023213419900_cei13546-bib-0004","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021121023213419900_cei13546-bib-0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2015.07.013","article-title":"Increased serum peroxiredoxin 5 levels in myasthenia gravis","volume":"287","author":"Uzawa","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand J Immunol"},{"key":"2021121023213419900_cei13546-bib-0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"2021121023213419900_cei13546-bib-0008","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"2021121023213419900_cei13546-bib-0009","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper t cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"2021121023213419900_cei13546-bib-0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells Interaction leads to ectopic gcs formation and anti-AChR antibody production: central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol Neurobiol"},{"key":"2021121023213419900_cei13546-bib-0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","article-title":"CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients","volume":"179","author":"Kohler","year":"2017","journal-title":"Clin Immunol"},{"key":"2021121023213419900_cei13546-bib-0012","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell-activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve"},{"key":"2021121023213419900_cei13546-bib-0013","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci Rep"},{"key":"2021121023213419900_cei13546-bib-0014","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2021121023213419900_cei13546-bib-0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"2021121023213419900_cei13546-bib-0016","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cyto.2012.03.018","article-title":"Th17 cell-derived IL-17 is dispensable for B cell antibody production","volume":"59","author":"Shibui","year":"2012","journal-title":"Cytokine"},{"key":"2021121023213419900_cei13546-bib-0017","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front Immunol"},{"key":"2021121023213419900_cei13546-bib-0018","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J Immunol"},{"key":"2021121023213419900_cei13546-bib-0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"J Autoimmun"},{"key":"2021121023213419900_cei13546-bib-0021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular Helper T Cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"2021121023213419900_cei13546-bib-0022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur J Immunol"},{"key":"2021121023213419900_cei13546-bib-0023","first-page":"1988","article-title":"CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome","volume":"7","author":"Jin","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"2021121023213419900_cei13546-bib-0024","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jneuroim.2014.11.011","article-title":"Association of circulating follicular helper T cells with disease course of NMO spectrum disorders","volume":"278","author":"Li","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0026","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/jtd.2016.03.03","article-title":"Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma","volume":"8","author":"Song","year":"2016","journal-title":"J Thorac Dis"},{"key":"2021121023213419900_cei13546-bib-0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10072-013-1460-3","article-title":"Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis","volume":"35","author":"Li","year":"2014","journal-title":"Neurol Sci"},{"key":"2021121023213419900_cei13546-bib-0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cei.12804","article-title":"Phenotypical characterization of regulatory T cells in humans and rodents","volume":"185","author":"Rodr\u00edguez-Perea","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2021121023213419900_cei13546-bib-0029","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fimmu.2015.00493","article-title":"FOXP3(+) Treg cells and gender bias in autoimmune diseases","volume":"6","author":"Nie","year":"2015","journal-title":"Front Immunol"},{"key":"2021121023213419900_cei13546-bib-0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J Clin Immunol"},{"key":"2021121023213419900_cei13546-bib-0031","doi-asserted-by":"crossref","first-page":"106130","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis","volume":"80","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2021121023213419900_cei13546-bib-0032","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/\u2013) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"2021121023213419900_cei13546-bib-0033","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann NY Acad Sci"},{"key":"2021121023213419900_cei13546-bib-0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-\u03b1","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"2021121023213419900_cei13546-bib-0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2021121023213419900_cei13546-bib-0036","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.20340","article-title":"Selective loss of regulatory T cells in thymomas","volume":"56","author":"Str\u00f6bel","year":"2004","journal-title":"Ann Neurol"},{"key":"2021121023213419900_cei13546-bib-0037","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10875-007-9147-2","article-title":"Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy","volume":"28","author":"Fattorossi","year":"2008","journal-title":"J Clin Immunol"},{"key":"2021121023213419900_cei13546-bib-0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2005.03.011","article-title":"Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma","volume":"164","author":"Luther","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0039","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2015.03.008","article-title":"Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity","volume":"281","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0040","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol"},{"key":"2021121023213419900_cei13546-bib-0041","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/08916934.2014.992517","article-title":"B cells produce less IL-10, IL-6 and TNF-\u03b1 in myasthenia gravis","volume":"48","author":"Yilmaz","year":"2015","journal-title":"Autoimmunity"},{"key":"2021121023213419900_cei13546-bib-0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine \u2013 40 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"2021121023213419900_cei13546-bib-0043","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"2021121023213419900_cei13546-bib-0044","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.132.6.2948","article-title":"Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line","volume":"132","author":"Yoshizaki","year":"1984","journal-title":"J Immunol"},{"key":"2021121023213419900_cei13546-bib-0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol"},{"key":"2021121023213419900_cei13546-bib-0046","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clineuro.2017.04.012","article-title":"Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis","volume":"157","author":"Zhang","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"2021121023213419900_cei13546-bib-0047","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11481-015-9638-5","article-title":"TIPE2 play a negative role in TLR4-mediated autoimmune T helper 17 cell responses in patients with myasthenia gravis","volume":"10","author":"Zhang","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"2021121023213419900_cei13546-bib-0048","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"2021121023213419900_cei13546-bib-0049","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000490855","article-title":"High frequency of Tc22 and Th22 cells in myasthenia gravis patients and their significant reduction after thymectomy","volume":"25","author":"Robat-Jazi","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"2021121023213419900_cei13546-bib-0050","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4049\/jimmunol.1901176","article-title":"IL-37 represses the autoimmunity in myasthenia gravis via directly targeting follicular Th and B cells","volume":"204","author":"Liu","year":"2020","journal-title":"J Immunol"},{"key":"2021121023213419900_cei13546-bib-0051","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jneuroim.2005.10.001","article-title":"Altered expression of Th1-type chemokine receptor CXCR3 on CD4+ T cells in myasthenia gravis patients","volume":"172","author":"Suzuki","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0052","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejphar.2009.10.040","article-title":"Clinical implications of the type 1\/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients","volume":"627","author":"Masuda","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"2021121023213419900_cei13546-bib-0053","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"2021121023213419900_cei13546-bib-0054","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3389\/fimmu.2017.01029","article-title":"Use of Toll-like receptor agonists to induce ectopic lymphoid structures in myasthenia gravis mouse models","volume":"8","author":"Robinet","year":"2017","journal-title":"Front Immunol"},{"key":"2021121023213419900_cei13546-bib-0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021121023213419900_cei13546-bib-0056","doi-asserted-by":"crossref","first-page":"e0123546","DOI":"10.1371\/journal.pone.0123546","article-title":"Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK","volume":"10","author":"Yilmaz","year":"2015","journal-title":"PLOS ONE"},{"key":"2021121023213419900_cei13546-bib-0057","doi-asserted-by":"crossref","first-page":"720","DOI":"10.5607\/en.2019.28.6.720","article-title":"B cell immunophenotyping and transcriptional profiles of memory B cells in patients with myasthenia gravis","volume":"2","author":"Min","year":"2019","journal-title":"Exp Neurobiol"},{"key":"2021121023213419900_cei13546-bib-0058","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"2021121023213419900_cei13546-bib-0059","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"2021121023213419900_cei13546-bib-0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021121023213419900_cei13546-bib-0061","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jneuroim.2016.05.004","article-title":"Impaired regulatory B cells in myasthenia gravis","volume":"297","author":"Sheng","year":"2016","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0062","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fneur.2017.00043","article-title":"Regulatory B cells in seropositive myasthenia gravis versus healthy controls","volume":"8","author":"Karim","year":"2017","journal-title":"Front Neurol"},{"key":"2021121023213419900_cei13546-bib-0063","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fneur.2017.00034","article-title":"B10 cell frequencies and suppressive capacity in myasthenia gravis are associated with disease severity","volume":"8","author":"Yi","year":"2017","journal-title":"Front Neurol"},{"key":"2021121023213419900_cei13546-bib-0064","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/acn3.645","article-title":"Regulatory B cells in myasthenia gravis are differentially affected by therapies","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2021121023213419900_cei13546-bib-0065","doi-asserted-by":"crossref","first-page":"73774","DOI":"10.18632\/oncotarget.17908","article-title":"Significance of B10 cell in patients with thymoma complicated with myasthenia gravis","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"2021121023213419900_cei13546-bib-0066","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"key":"2021121023213419900_cei13546-bib-0067","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021121023213419900_cei13546-bib-0068","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.nmd.2017.06.012","article-title":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","volume":"27","author":"Muto","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2021121023213419900_cei13546-bib-0069","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"2021121023213419900_cei13546-bib-0070","doi-asserted-by":"crossref","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"2021121023213419900_cei13546-bib-0071","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"2021121023213419900_cei13546-bib-0072","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2021121023213419900_cei13546-bib-0073","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/mus.25458","article-title":"Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment","volume":"55","author":"Alboini","year":"2017","journal-title":"Muscle Nerve"},{"key":"2021121023213419900_cei13546-bib-0074","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13311-016-0476-9","article-title":"A novel fusion protein, AChR-Fc, ameliorates myasthenia gravis by neutralizing antiacetylcholine receptor antibodies and suppressing acetylcholine receptor-reactive B cells","volume":"14","author":"Homma","year":"2017","journal-title":"Neurotherapeutics"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13546","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/3\/366\/41635029\/cei13546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/3\/366\/41635029\/cei13546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:40:48Z","timestamp":1697096448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/203\/3\/366\/6403208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,3]]},"published-print":{"date-parts":[[2021,2,10]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13546","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,12,3]]}}}